RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Classic Hodgkin Lymphoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Nivolumab with doxorubicin, vinblastine, and dacarbazine in older adults with classic Hodgkin lymphoma: do S1826 results hold up in the real world?
Yizhe Xu et al., UNC Libraries (15 October 2026)
https://doi.org/10.17615/h3wp-jj95
- 2.
Survival by Design: Cell Fate Dynamics in Classical Hodgkin Lymphoma.
Seleusan Matei et al., Critical reviews in oncology/hematology (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42880615/
- 3.
Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826).
Ahmed Sairah et al., Blood advances (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42526889/
- 4.
Molecular Landscape of Classical Hodgkin Lymphoma: From Genetic Lesions to Biologically Defined Subtypes
Maria Cristina Pirosa et al., Cancers (9 October 2026)
https://doi.org/10.3390/cancers18203256
- 5.
Nivolumab with doxorubicin, vinblastine, and dacarbazine in older adults with classic Hodgkin lymphoma: do S1826 results hold up in the real world?
Torka Pallawi et al., Haematologica (8 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42845039/
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
NCT06504394 · Active (not recruiting) · Phase 2 · Merck Sharp & Dohme LLC
Ages 18 and over
https://clinicaltrials.gov/study/NCT06504394
- 2.
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
NCT06018129 · TERMINATED · Phase 1 / Phase 2 · Genmab
Ages 16 and over
https://clinicaltrials.gov/study/NCT06018129
- 3.
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
NCT05508867 · Completed · Phase 2 · Merck Sharp & Dohme LLC
Ages 18 and over
https://clinicaltrials.gov/study/NCT05508867
- 4.
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
NCT05008224 · Completed · Phase 2 · Merck Sharp & Dohme LLC
Ages 18 and over
https://clinicaltrials.gov/study/NCT05008224
- 5.
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT04318080 · Completed · Phase 2 · BeiGene
Ages 18 and over
https://clinicaltrials.gov/study/NCT04318080
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Classic Hodgkin Lymphoma
Classic Hodgkin lymphoma is a cancer of the lymphatic system, the network that helps the body fight infection. It is marked by abnormal Reed-Sternberg cells and usually appears as painless swollen lymph nodes, often in the neck, chest or armpits. Treatment usually involves chemotherapy, sometimes with radiotherapy or immunotherapy, and many people are cured.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Older adults (OA, ≥60 years) with classic Hodgkin lymphoma (cHL) have historically experienced inferior outcomes compared to younger patients. Nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) has demonstrated high efficacy in clinical trials, but real-world data in OA are limited. We conducted a multicenter retrospective study across 20 centers in patients with newly diagnosed advanced stage cHL treated with NAVD and analyzed outcomes in OA across the aging spectrum. Among 327 total patients, 81 (25%) were ≥60 years, with most OA presenting with stage IV disease (58%) and B symptoms (57%). Anygrade and ≥grade 3 AEs occurred in 88% and 67% of OA, respectively. Prophylactic growth factors were used in most OA (82%) which led to low rates of febrile neutropenia (12%) and infection (12%) despite 52% ≥grade 3 neutropenia. Immune-related AEs occurred in 29% (12% ≥grade 3) and treatment was discontinued due to toxicity in 10% of OA. Interim overall (ORR) and complete response rates (CRR) were 100% and 81.6%, end-of-treatment rates were 88% and 82.6%, respectively. At a median follow-up of 12.6 months, 1-year progression-free survival (PFS) and overall survival (OS) in OA were 91.5% and 98.6%, respectively. OS was inferior in OA compared with patients.
Common Questions
What is Classic Hodgkin Lymphoma?
Classic Hodgkin lymphoma is a cancer of the lymphatic system, the network that helps the body fight infection. It is marked by abnormal Reed-Sternberg cells and usually appears as painless swollen lymph nodes, often in the neck, chest or armpits. Treatment usually involves chemotherapy, sometimes with radiotherapy or immunotherapy, and many people are cured.
How many clinical trials are available for Classic Hodgkin Lymphoma?
RareWays currently indexes 155 clinical trials for Classic Hodgkin Lymphoma, of which 23 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Classic Hodgkin Lymphoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Classic Hodgkin Lymphoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.